The short-chain fatty acid uptake fluxes by mice on a guar gum supplemented diet associate with amelioration of major biomarkers of the metabolic syndrome by den Besten, Gijs et al.
The Short-Chain Fatty Acid Uptake Fluxes by Mice on a
Guar Gum Supplemented Diet Associate with
Amelioration of Major Biomarkers of the Metabolic
Syndrome
Gijs den Besten1,3, Rick Havinga1, Aycha Bleeker1,4, Shodhan Rao1, Albert Gerding2,
Karen van Eunen1,3,4, Albert K. Groen1,2,3, Dirk-Jan Reijngoud1,2,3, Barbara M. Bakker1,3*
1Center for Liver, Digestive and Metabolic Diseases, Department of Pediatrics & Systems Biology Center for Energy Metabolism and Ageing, University of Groningen,
University Medical Center Groningen, Groningen, The Netherlands, 2Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen,
Groningen, The Netherlands, 3Netherlands Consortium for Systems Biology, Amsterdam, The Netherlands, 4 Top Institute Food and Nutrition, Wageningen, The
Netherlands
Abstract
Studies with dietary supplementation of various types of fibers have shown beneficial effects on symptoms of the metabolic
syndrome. Short-chain fatty acids (SCFAs), the main products of intestinal bacterial fermentation of dietary fiber, have been
suggested to play a key role. Whether the concentration of SCFAs or their metabolism drives these beneficial effects is not
yet clear. In this study we investigated the SCFA concentrations and in vivo host uptake fluxes in the absence or presence of
the dietary fiber guar gum. C57Bl/6J mice were fed a high-fat diet supplemented with 0%, 5%, 7.5% or 10% of the fiber guar
gum. To determine the effect on SCFA metabolism, 13C-labeled acetate, propionate or butyrate were infused into the cecum
of mice for 6 h and the isotopic enrichment of cecal SCFAs was measured. The in vivo production, uptake and bacterial
interconversion of acetate, propionate and butyrate were calculated by combining the data from the three infusion
experiments in a single steady-state isotope model. Guar gum treatment decreased markers of the metabolic syndrome
(body weight, adipose weight, triglycerides, glucose and insulin levels and HOMA-IR) in a dose-dependent manner. In
addition, hepatic mRNA expression of genes involved in gluconeogenesis and fatty acid synthesis decreased dose-
dependently by guar gum treatment. Cecal SCFA concentrations were increased compared to the control group, but no
differences were observed between the different guar gum doses. Thus, no significant correlation was found between cecal
SCFA concentrations and metabolic markers. In contrast, in vivo SCFA uptake fluxes by the host correlated linearly with
metabolic markers. We argue that in vivo SCFA fluxes, and not concentrations, govern the protection from the metabolic
syndrome by dietary fibers.
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Introduction
The shift in diet in Western and developing countries from a
traditional high-fiber, low-fat, low-calorie diet towards a low-fiber,
high-fat, high-calorie diet is accompanied with a growing
prevalence of the metabolic syndrome comorbidities: obesity,
hypertension, dyslipidemia and insulin resistance [1,2]. Epidemi-
ological and large observational studies reported an inverse
correlation between dietary fiber intake and body weight, insulin
resistance, hypertension and dyslipidemia [3]. The dietary fiber
guar gum is especially promising, as it has been shown to decrease
hypercholesterolemia, hyperglycemia and obesity in multiple
experiments in both rodents and humans [4,5]. The molecular
mechanisms by which guar gum induces these effects constitute an
active field of research. Short-chain fatty acids (SCFAs), the main
products of intestinal bacterial fermentation of dietary fiber, have
been suggested to play a key role in these beneficial effects [6].
SCFAs are saturated aliphatic organic acids that consist of 1–6
carbons of which acetate (C2), propionate (C3) and butyrate (C4)
are the most abundant ($95%) [7]. In the last decades it became
apparent that SCFAs might play a key role in the prevention and
treatment of the metabolic syndrome, bowel disorders and certain
types of cancer [8–14]. The effects of dietary fiber on the host are
mostly studied by looking at the fecal or colonic SCFA
concentrations and the host physiology. However, increased
concentrations of SCFAs do not always correlate to beneficial
host effects. For instance, genetically obese ob/ob mice and obese
human subjects had increased concentrations of cecal and fecal
SCFAs as compared to lean controls [15–17], while germ-free
mice and rats had low SCFA concentrations and were protected
from diet-induced obesity [18,19]. Recently, Teixeira et al. [20]
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even suggested that human fecal SCFA concentrations in women
are positively correlated with metabolic syndrome risk factors such
as adiposity, waist circumference and HOMA index. These results
raise the question if SCFAs are involved in the beneficial effect of
dietary fibers. It is important to note, however, that at steady-state
the cecal or fecal SCFA concentrations not necessarily reflect the
SCFA uptake fluxes by the host. It is known that SCFAs exert their
effects not only directly in the gut, but also via other organs like the
liver and adipose tissue [6]. For the latter effect the cecal
concentration is of less importance than the amount of SCFAs that
is transported into the host. It is plausible that the SCFA host
uptake fluxes are involved in the beneficial effect of dietary fibers.
In vivo flux measurements, however, are challenging. Therefore,
SCFA production fluxes have been measured mostly in vitro by
exposing an inoculum of gut microbiota to dietary fiber. The
disadvantages of this method are that i) during isolation of the
anaerobic gut microbiota the diversity decreases, ii) raw substrates
are not modified as it normally occurs in vivo in the upper part of
the gastrointestinal tract, iii) products accumulate during fermen-
tation due to the lack of host uptake mechanisms and iv) the
uptake fluxes by the host, which we ultimately need to know,
cannot be determined [21,22].
In this study we present a novel method to determine in vivo
SCFA fluxes under different dietary conditions. The method was
based on infusion of tracer amounts of 13C-labeled acetate,
propionate or butyrate into the cecum and the results of all three
infusions were combined in a single steady-state isotope model.
This allowed us to quantify how the intake of 0%, 5%, 7.5% or
10% of the dietary fiber guar gum affected the SCFA fluxes and
how these correlated with major biomarkers of the metabolic
syndrome.
Materials and Methods
Ethics Statement
The national and institutional guidelines for the care and use of
animals were followed, and the experimental procedures were
reviewed and approved by the Ethics Committees for Animal
Experiments of the University of Groningen, The Netherlands
(ethics registration code 5887). All efforts were made to minimize
suffering.
Animals and Experimental Design
Male C57Bl/6J mice (Charles River, L’Arbresle Cedex,
France), 2 months of age, were housed in a light- and
temperature-controlled facility (lights on 6:30 a.m. to 6:30 p.m.,
21uC). During 6 weeks mice were fed a high-fat semi-synthetic diet
(based on D12451 [23], Research Diet Services, Wijk Bij
Duurstede, The Netherlands) in which 0, 5, 7.5 or 10% (w/w)
guar gum (Viscogum MP 41230, Cargill, United States) replaced
an equivalent amount of corn starch. In this way we ensured that
only the fiber content was varied while the total polysaccharide
and calorie content of the diets remained equal. Mice had free
access to food and drinking water. The Ethics Committee for
Animal Experiments of the University of Groningen approved the
experimental procedures.
Plasma and tissue sampling
Mice were fasted from 8–12 a.m. Blood glucose concentrations
were measured with a EuroFlash meter (Lifescan Benelux, Beerse,
Belgium). Blood samples were drawn by tail bleeding into
heparinized tubes. Blood was centrifuged (40006g for 10 min at
4uC) and plasma was stored at 220uC. Plasma insulin levels were
determined using ELISA (ALPCO Diagnostics, Salem, United
States) and HOMA-IR was calculated (IR = (fasting insulin in
mU/L x fasting glucose in mM)/22.5). Plasma triglycerides
concentrations were determined using a commercially available
kit (Roche). Hepatic TG content was determined after lipid
extraction [24].
Hyperinsulinemic-euglycemic clamps
Mice were operated for jugular vein catherization after 6 weeks
on a 0% or 10% guar gum diet and insulin sensitivity was
determined as previously described [25]. In brief, mice were fasted
for 9 h and were infused for a 3 h basal period with an isotonic
saline solution containing [U-13C] glucose (7 mM), (Cambridge
Isotope Laboratories, Andover, MA) at an infusion rate of
0.54 ml/h. For the hyperinsulinemic condition, solutions were
changed after 3 h, and mice were subjected to a 3 h hyperinsu-
linemic period by infusing an isotonic saline solution containing
insulin (44 mU/ml, Actrapid; Novo Nordisk, Denmark), somato-
statin (40 mg/ml; UCB, The Netherlands) and 1% BSA (Sigma, St.
Louis, MO) at a constant rate of 0.135 ml/h. During hyperinsu-
linemia, euglycemia was kept by infusion of a second solution that
contained 27% glucose (1.6 M) and 3% [U-13C]glucose (50 mM)
at an adjustable rate to maintain plasma glucose levels. During the
experiment, blood glucose levels were measured every 15 min in
blood drops collected by tail tip bleeding. Every 30 min, blood
spots for GC-MS analysis were taken by tail tip bleeding on filter
paper, air dried, and stored at room temperature until further
analysis. Urine samples were collected on filter paper at hourly
intervals. Glucose fluxes were calculated using mass isotopologue
distribution analysis (MIDA) as previously described [26].
Cecal infusion experiment
After 6 weeks on diet, mice were equipped with a permanent
cecum catheter and allowed a recovery period of at least 5 days as
described previously [27]. Cecal cannulas were flushed daily with
phosphate buffered saline. On the day of the experiment, mice
were individually housed and fasted from 6:00 to 10:00 a.m. All
infusion experiments were performed in conscious, unrestrained
mice. For each dietary treatment group, three different groups
received solutions of phosphate buffered saline containing either
sodium [1-13C]acetate (3 mM, 99 atom %, Sigma-Aldrich),
sodium [2-13C]propionate (1.5 mM, 99 atom %, Sigma-Aldrich)
or sodium [2,4-13C2]butyrate (0.6 mM, 99 atom %, Sigma-
Aldrich) via the cecum catheter at an infusion rate of 0.2 ml/h.
After 6 h of infusion, animals were sacrificed by cardiac puncture
under isoflurane anesthesia. Cecum content was removed quickly,
frozen in liquid nitrogen, and stored at -80uC for SCFA
enrichment determination.
Determination of SCFA concentrations and enrichments
Cecal concentrations and enrichments of SCFAs were measured
as previously described [27]. In short, cecum content was
centrifuged and 25 ml of supernatant was spiked with 25 ml of
internal standard (17.3 mM hydroxyisocapronic acid) and 5 ml of
20% 5-sulfosalicyclic acid. After a 10 min centrifugation the
supernatant was acidified with 2.5 ml 37% HCl and SCFA were
extracted with 2 ml diethylether. Derivatization was performed
overnight with 500 ml supernatant and 50 ml of N-tert-Butyldi-
methylsilyl-N-methyltrifluoroacetamide (MTBSTFA).
Mass isotopologue distributions were measured in an Agilent
5975 series GC/MSD (Agilent Technologies). The gas chromato-
graph was equipped with a ZB-1 column (Phenomenex). Mass
spectrometry analysis was performed by electron capture negative
ionization with methane as the moderating gas. Ions monitored
were m/z 117–118 for acetate,
m/z 131–132 for propionate and
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m/z 145–147 for butyrate. The normalized mass isotopologue
distributions measured by GC-MS (m0-mx) were corrected for
natural abundance of 13C by multiple linear regression according
to Lee et al. [28] to obtain the excess fractional distribution of mass
isotopologues (M0-Mx).
Gene expression levels
RNA was extracted from cecum tissue using Tri reagent (Sigma-
Aldrich, St. Louis, MO) and converted into cDNA by a reverse
transcription procedure using M-MLV and random primers
according to the manufacturer’s protocol (Sigma-Aldrich). For
quantitative PCR (qPCR), cDNA was amplified using the appro-
priate primers and probes. Taqman RT-PCR primer and probe
were used to determine mRNA for MCT-1 (Mm01315398_m1),
SMCT-1 (Mm00520629_m1), PEPCK (Mm01247058_m1), G6Pase
(Mm00839363_m1), PC (Mm00500992_m1), HK (Mm00439344
_m1), PK (Mm00443090_m1), FASN (Mm01204974_m1), ACC1
(Mm01304257_m1), ACC2 (Mm01204671_m1) and ELOVL6
(Mm00851223_s1). mRNA levels were calculated relative to 36b4
(Mm00725448_s1) expression and normalized for expression levels of
mice fed the control diet.
Statistics
All data are presented as mean values 6 SEM. Statistical
analysis was assessed by one-way ANOVA using the Tukey test for
post-hoc analysis. For analysis of correlations, Spearman’s rank
test was used. Statistical significance was defined as a p value
below 0.05. Data were analyzed with SPSS v.20 software.
Results
Guar gum protects against diet-induced obesity and
insulin resistance in a dose-dependent manner
Supplementation of a high-fat diet with guar gum dose-
dependently decreased body weight of mice after 6 weeks
treatment (Figure 1A), with a maximal effect at the highest dose
of the fiber (13% decrease at 10% guar gum vs. control; p,0.001).
In concert, adipose/body weight ratio decreased dose-dependently
by guar gum treatment (70% decrease at 10% guar gum vs.
control; p,0.001; Figure 1B). Triglycerides in plasma and liver
also decreased with an increasing dose of guar gum (46% decrease
at 10% guar gum vs. control; p,0.001 and 45% decrease at 10%
guar gum vs. control; p,0.01, respectively; Figure 1C and 1D).
Expression of genes involved in hepatic fatty acid synthesis was
decreased with increasing dosage of guar gum, while no effect was
observed for genes involved in fatty acid oxidation (Table 1).
Fasted plasma glucose and insulin levels decreased dose-depen-
dently by guar gum treatment (27% decrease at 10% guar gum vs.
control; p,0.001 and 49% decrease at 10% guar gum vs. control;
p,0.01, respectively; Figure 1E and 1F). Expression of genes
involved in hepatic gluconeogenesis was decreased with increasing
dosage of guar gum, while expression of genes involved in
glycolysis were increased in a guar gum dose-dependent manner
(Table 1). The homeostasis model assessment for insulin resistance
(HOMA-IR) decreased with an increasing dose of guar gum (64%
decrease at 10% guar gum vs. control; p,0.001; Figure 1G). To
quantify insulin sensitivity and to discriminate between the effects
of guar gum on liver and peripheral insulin action, we performed
hyperinsulinemic euglycemic clamp studies under matched insulin
exposure for control and 10% guar gum fed mice. The glucose-
infusion rate required for maintaining euglycemia (a measure of
whole-body insulin sensitivity) in guar gum-fed mice was
significantly higher than that in control mice (164% increase at
10% guar gum vs. control; p,0.001; Figure 1H). While the
hepatic glucose production rate during the clamp was similar in
both groups (Ra in Figure 1I), the degree to which insulin
stimulated the rate of glucose uptake by peripheral tissues
(primarily muscle and adipose tissue) was much higher in guar
gum-fed mice (130% increase at 10% guar gum vs. control; p,
0.001; Rd in Figure 1I). All groups of mice treated with guar gum
showed an approximately 2.5-fold increase in cecal mass content
compared to the control diet (167% increase at 10% guar gum vs.
control; p,0.01; Figure 1J). However, in this respect no differ-
ences were observed between the different guar gum groups. Cecal
concentrations of acetate (176% increase at 10% guar gum vs.
control; p,0.001), propionate (207% increase at 10% guar gum
vs. control; p,0.001) and butyrate (174% increase at 10% guar
gum vs. control; p,0.05) were increased in the three guar gum
groups compared to the control group (Figure 1K), but again no
significant differences were observed between the different guar
gum groups. The cecal mRNA expression of two known colonic
SCFA transporters, monocarboxylate transporter 1 (MCT-1) and
sodium-coupled MCT-1 (SMCT-1), were increased in the guar
gum groups compared to the control group, with the highest
expressions in the 5% guar gum group (Table 1).
Short-chain fatty acid concentrations correlate with cecal
transporter mRNA expression but not with metabolic
syndrome markers
To investigate if the concentration of cecal SCFAs associate
with markers of the metabolic syndrome (i.e. body weight, adipose
weight, triglycerides, glucose, insulin and HOMA-IR), we plotted
the concentration of the three SCFA against the metabolic
syndrome markers of the different treatment groups. Cecal
acetate, propionate and butyrate concentrations did not correlate
with body weight, adipose weight, triglycerides, glucose, insulin
and HOMA-IR (p.0.05; Figures 2 and S1). In contrast, all three
SCFAs correlated significantly with SMCT-1 and MCT-1
expression but not with genes involved in gluconeogenesis,
glycolysis, fatty acid synthesis and fatty acid oxidation (Table
S1). We hypothesized that the physiological effect of guar gum was
not exerted via the colonic SCFA concentration, but rather via the
SCFAs that are produced by the microbiota and taken up by the
host. Therefore, we set out to determine these fluxes in vivo.
A model to determine short-chain fatty acid production
and uptake fluxes
We designed an animal experiment to determine in vivo fluxes
of SCFA production, interconversion and uptake by the host,
based on isotope dilution and incorporation. We infused separately
tracer amounts of [1-13C]acetate, [2-13C]propionate or
[2,4-13C2]butyrate during 6 h into the cecum of conscious,
unrestrained mice and measured the label content in the cecal
SCFAs at the end of the infusion period as described before [27].
Infusion of any of the labeled SCFAs resulted in label incorpo-
ration in all three cecal SCFAs (Figure 3A). This indicates that
there is interconversion of labeled SCFAs by the gut bacteria. To
calculate the in vivo fluxes of bacterial SCFA production and
consumption by the host we constructed a mathematical model
that accounts for this bacterial label conversion (Figure 3B).
Starting from the assumption that the isotopic measurements were
performed during mass and isotopic steady state, flux balance
equations were derived for each of the labeled and unlabeled
SCFAs during the tracer infusions of [1-13C] acetate, [2-13C]
propionate or [2,4-13C2] butyrate. We further assumed that the
labeled tracers did not affect the total mass fluxes and hence these
SCFA Fluxes Associate with Metabolic Markers
PLOS ONE | www.plosone.org 3 September 2014 | Volume 9 | Issue 9 | e107392
should be identical in the three infusion experiments. Based on the
observation that double-labeled butyrate was detected after
infusion of acetate and propionate, we assumed that 2 acetate or
propionate molecules were used for the production of 1 butyrate
molecule. An alternative model in which the stoichiometry of the
interconversion between propionate and butyrate was changed
gave similar results, indicating that our conclusions do not depend
critically on this assumption (Text S1). This was not surprising
because there was hardly any interconversion flux between
propionate and butyrate. We solved the full set of flux balance
equations for the in vivo SCFA production, interconversion and
uptake fluxes with the Generalized Reduced Gradient (GRG)
Nonlinear Solver algorithm [29]. A full description of the model
and computational analysis is given in Text S1.
In vivo bacterial short-chain fatty acid production and
host fluxes
The above described model-based method to measure in vivo
fluxes and SCFA interconversion was applied to the different
groups of mice treated with guar gum and to the control group for
comparison (Figure 3C). The production and uptake fluxes of
acetate were highest, followed by the propionate and butyrate
fluxes. This corresponded with the order of SCFA concentrations
(Figure 1K). The production flux of acetate was higher than its
uptake flux, since 7.1% of the acetate was converted into butyrate
(Figure 3C and Table 2), revealing microbial cross-feeding. The
production and uptake fluxes of propionate were almost identical,
since there was little conversion of propionate into the other
SCFAs and back (Figure 3C and Table 2). Interestingly, approx-
imately 50% of butyrate was not produced directly from fibers but
rather via dimerization of acetate (Figure 3C and Table 2).
The guar gum treatment increased all the fluxes of SCFA
production and uptake by the host in a dose-dependent manner
(Figure 3C), with the highest fluxes at the highest fiber dose. The
relative increase was highest for the propionate production and
uptake fluxes (787% increase at 10% guar gum vs. control; p,
0.001 and 761% increase at 10% guar gum vs. control; p,0.001,
respectively) followed by the acetate production and uptake fluxes
(514% increase at 10% guar gum vs. control; p,0.001 and 518%
increase at 10% guar gum vs. control; p,0.001, respectively) and
the butyrate production and uptake fluxes (273% increase at 10%
guar gum vs. control; p,0.001 and 461% increase at 10% guar
gum vs. control; p,0.001, respectively).
Changes in metabolic syndrome markers were inversely
correlated with in vivo short-chain fatty acid fluxes
None of the in vivo SCFA fluxes correlated with the cecal SCFA
concentrations or expression of the cecal SCFA transporters (p.
0.05; Figures S2A and S3A and Tables S2 and S3, respectively).
However, in vivo SCFA host uptake fluxes did significantly and
inversely correlate with body weight, adipose weight, triglycerides,
fasted glucose and insulin levels, and HOMA-IR (p,0.05;
Figures 4 and S2). In concert, in vivo SCFA host uptake fluxes
significantly correlated with genes involved in glycolysis and
inversely with genes involved in gluconeogenesis and fatty acid
synthesis (Table S2). No correlation was found for fatty acid
Figure 1. Effect of dietary supplementation with guar gum on mouse physiology after 6 weeks on a high-fat diet. (A) Body weight for
the different guar gum groups. (B) Adipose weight body weight ratio (AW/BW) for the different guar gum groups. Triglycerides in plasma (C) and liver
(D). Plasma glucose (E) and insulin (F) levels after a 4-hour fast. Blood glucose and insulin levels were used to determine insulin sensitivity through
HOMA-IR (G). (H) Average glucose infusion rates needed to maintain euglycemic conditions during hyperinsulinemic-euglycemic clamps (HIEC)
conditions for the 0% and 10% guar gum groups. (I) Hepatic glucose production (Ra) and peripheral glucose disposal (Rd) rate during HIEC
conditions. (J) Cecal content and (K) cecal SCFA concentrations. Data represent means 6 SEM for n= 7–8. Different letters indicate significant
differences between groups (at least p,0.05).
doi:10.1371/journal.pone.0107392.g001
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oxidation genes (Table S2). Similar results were found for the in
vivo SCFA production fluxes (Figure S3 and Table S3). The
correlation was better for the uptake fluxes by the host than for the
microbial production fluxes, however. The difference between
uptake and production fluxes was due to microbial interconver-
sion. The correlation was generally increasing from acetate to
butyrate to propionate. Altogether, these data suggest that in vivo
SCFA fluxes, and not concentrations, are key to understand the
beneficial effects of fibers on metabolic syndrome markers.
Discussion
In this paper we demonstrate that the rate of uptake of SCFAs
directly correlates with amelioration of symptoms clustered in the
metabolic syndrome. Beneficial effects of SCFAs have been
frequently suggested in the literature, but evidence for this
contention has been lacking since physiological effects did not
correlate with luminal SCFA concentrations. By determining the
in vivo SCFA fluxes we show for the first time that in vivo SCFA
fluxes rather than concentrations correlate in an inverse manner
with biomarkers of the metabolic syndrome. Here we will discuss
how this adds to the evidence for a causal relation between fiber
intake, SCFA fluxes and attenuation of metabolic syndrome
markers.
Human randomized controlled clinical trials showed that guar
gum supplementation decreased body weight and fasting plasma
glucose and insulin concentrations in both healthy and metabolic
syndrome patients [5,30,31]. Here, we show that increasing the
content of guar gum in a high-fat diet resulted in a dose-dependent
decrease in body weight, adipose weight, plasma and hepatic
triglycerides, fasting plasma glucose and insulin concentrations
and HOMA-IR, together indicating an improvement of the
metabolic syndrome. To date, no molecular mechanism for these
beneficial effects of guar gum has been described. Two lines of
evidence suggest that SCFAs exert a key role in this beneficial
effect. First, SCFAs are the main end products of microbial
fermentation of dietary fibers in the intestine [6]. Second, SCFA
supplementation in the diet protects against dietary-induced
obesity and insulin resistance [9,32], suggesting that microbial
SCFAs might do the same. The question then arises how SCFAs
might mediate the observed dose-dependent effect of dietary fibers
whilst their concentrations do not correlate with the fiber dose and
metabolic syndrome markers [17,19,20,33]. It is well known that
SCFAs regulate the physiology of the host not only via direct
effects in the colon, but also via other organs in the host, such as
liver and adipose tissue [6]. Indeed, we showed that guar gum
supplementation decreased hepatic triglycerides and expression of
hepatic genes involved in fatty acid synthesis, indicating a
decreased hepatic lipogenesis [34]. In addition, the decreased
lipogenesis parameters were inversely correlated with the in vivo
SCFA uptake fluxes by the host. Together with the fact that
dietary supplementation with SCFAs has been shown to activate
AMP-activated protein kinase and subsequently decrease lipogen-
esis in the liver [6,9,35,36], this suggests that the SCFAs that are
taken up by the host are responsible for the decrease in hepatic
triglycerides. Next to fatty acid metabolism, we demonstrated that
Table 1. Gene expression for cecal SCFA transport, hepatic gluconeogenesis and glycolysis and hepatic fatty acid synthesis and
oxidation for the different guar gum groups.
Control Guar Gum 5% Guar Gum 7.5% Guar Gum 10%
SCFA transport
Mct-1 1.0060.13a 1.6260.06b 1.3260.13a 1.2360.06a
Smct-1 1.0060.09a 4.5560.48b 4.1460.31b 3.0860.13c
Gluconeogenesis
Pepck 1.0060.11a 0.9060.11a 0.6460.05b 0.5060.08c
G6Pase 1.0060.14a 0.7060.10b 0.4760.11c 0.3360.03c
PC 1.0060.11a 0.8760.04a 0.7960.07b 0.7460.06b
Glycolysis
HK 1.0060.07a 1.5060.19a 2.0860.33b 3.0260.53c
PK 1.0060.10a 1.1060.12a 1.4560.14b 1.6960.19b
Fatty acid synthesis
Fasn 1.0060.04a 0.7160.06b 0.6960.08b 0.5160.05c
Acc1 1.0060.08a 0.8460.05a 0.7360.08b 0.6660.06b
Acc2 1.0060.09a 0.8860.10a 0.8360.08b 0.5660.05b
Elovl6 1.0060.14a 0.8660.07a 0.7560.07b 0.6760.08b
Fatty acid oxidation
Cpt-1a 1.0060.07a 0.8860.11a 0.8460.06a 0.8460.07a
Mcad 1.0060.06a 1.1060.12a 1.0160.09a 1.0160.10a
Lcad 1.0060.04a 0.9460.08a 0.9660.07a 0.9460.07a
Aox 1.0060.04a 1.0360.04a 1.1260.07a 0.9660.06a
Mct-1, Monocarboxylate transporter 1; Smct-1, sodium-coupled monocarboxylate transporter 1; Pepck, phosphoenolpyruvate carboxykinase; G6Pase, glucose
6-phosphatase; PC, pyruvate carboxylase; HK, hexokinase; PK, pyruvate kinase; Fasn, fatty acid synthase; Acc1, acetyl-CoA carboxylase 1; Acc2, acetyl-CoA carboxylase 2;
Elovl6, fatty acid elongase 6; Cpt-1a, carnitine palmitoyltransferase 1a; Mcad, medium-chain acyl coA dehydrogenase; Lcad, long-chain acyl coA dehydrogenase; Aox,
acyl-CoA oxidase.
Data represent means 6 SEM for n = 7–8. When groups have a different superscript a, b or c associated, the results differ significantly between them (at least p,0.05).
doi:10.1371/journal.pone.0107392.t001
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guar gum improved glucose handling, via increased insulin
sensitivity. The latter was mediated by peripheral tissues, most
likely peripheral muscle and adipose tissue. This is in agreement
with the finding that dietary fibers and SCFAs increased oxidative
metabolism and insulin sensitivity in muscle and adipose tissue
[9,37–39].
While our data suggest that the physiological effect of guar gum
is mediated via the uptake fluxes of SCFA into the host, we do not
explain what causes the dose-dependent SCFA uptake fluxes in the
first place. In general, the uptake rate of a metabolite depends on
its own concentration as well as on the capacity and kinetics of its
transporter. At steady state, neither the concentration of the
SCFAs nor the mRNA expression of the SCFA transporters
MCT-1 and SMCT-1 correlated with the SCFA flux. Cecum
content and thereby uptake surface did not correlate with the
fluxes either. We have not measured transporter kinetics, which
leaves the possibility that SCFA transport is regulated at the
protein level. Even then, the question remains how SCFAs affect
the transporter capacity at protein level, if SCFA concentrations
are constant. We note that all our measurements were done after 6
weeks on a high-fat diet, and we do not know how the organism
evolved towards the measured state. Possibly the SCFA concen-
trations underwent dose-dependent dynamics during the 6 weeks
in which they adapted to a new steady state through a strong
feedback control, a phenomena known as ‘‘perfect adaptation’’
[40,41]. With a pKa of ,4.8 and a luminal pH around 6.0
Figure 2. Cecal SCFA concentrations correlations. Correlation of cecal acetate, propionate and butyrate concentration with body weight (A),
AW/BW (B), hepatic triglycerides (C) and HOMA-IR (D). The Spearman’s correlation coefficient was calculated and the significance level was set at p,
0.05.
doi:10.1371/journal.pone.0107392.g002
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(pH 5.5–6.5) the major part of SCFAs is present in the dissociated
form [42]. The protons that dissociate from the SCFAs are
buffered by an unknown type of transporters that couples the
import of SCFA anions to bicarbonate secretion into the intestinal
lumen [6]. By modifying the buffer capacity it is thereby possible
to increase the uptake of SCFAs and achieve ‘‘perfect adaptation’’.
An alternative possibility, which we cannot exclude, is that the
concentration of another metabolite co-varies with the uptake
fluxes and takes part in the actual causal mechanism. Next to
SCFAs, the gut microbiota produces many metabolites which are
involved in the regulation of multiple host metabolic pathways
[43]. However, obvious candidates such as lactate were hardly
detectable (data not shown).
Figure 3. In vivo SCFA fluxes. (A) Enrichment of cecal SCFAs after 6 h infusion with [1-13C] acetate, [2-13C] propionate or [2,4-13C2] butyrate for the
different guar gum groups. (B) Schematic overview of the model used to determine in vivo bacterial SCFA production, interconversion and host
uptake fluxes at steady state. Each reaction is represented by a flux (v, for a detailed description see Text S1). (C) In vivo SCFA production and uptake
fluxes for the different guar gum groups after 6 weeks on high-fat diet. Data represent means 6 SEM for n = 7–8. Different letters indicate significant
differences between groups (at least p,0.05).
doi:10.1371/journal.pone.0107392.g003
Table 2. SCFA interconversion fluxes (mmol/kg/h) for the different Guar Gum groups.
Guar Gum content (%)
0 5 7.5 10
Acetate R Butyrate 0.1160.01 0.1460.01 0.3260.02 0.4760.02
Butyrate R Acetate 0.0060.00 0.0060.00 0.0060.01 0.0060.02
Propionate R Acetate 0.0060.00 0.0060.01 0.0060.06 0.0060.01
Acetate R Propionate 0.0060.01 0.0060.01 0.0060.04 0.0060.05
Propionate R Butyrate 0.0060.00 0.0060.00 0.0060.00 0.0060.00
Butyrate R Propionate 0.0060.00 0.0060.00 0.0060.00 0.0060.01
Data represent means 6 SEM for n = 7–8.
doi:10.1371/journal.pone.0107392.t002
SCFA Fluxes Associate with Metabolic Markers
PLOS ONE | www.plosone.org 7 September 2014 | Volume 9 | Issue 9 | e107392
In conclusion, our data clearly showed that in vivo SCFA fluxes
and not SCFA concentrations are inversely correlated to metabolic
syndrome markers. Together with the known causal effect of
increased SCFA in the diet, this provides strong evidence for a
causal relation between SCFA uptake flux and metabolic
syndrome. Further research should elucidate the role of additional
molecular factors that mediate this effect, as well as the mechanism
explaining the dose-dependency of the uptake fluxes.
Supporting Information
Figure S1 Correlation of cecal concentrations of acetate,
propionate and butyrate with plasma triglycerides (A), plasma
glucose (B) and plasma insulin levels (C). The Spearman’s
correlation coefficient was calculated and the significance level
was set at p,0.05.
(TIF)
Figure S2 Correlation of acetate, propionate and butyrate host
uptake fluxes with cecal concentrations of acetate, propionate and
butyrate, respectively (A). Correlation of acetate, propionate and
butyrate host uptake fluxes with plasma triglycerides (B), plasma
glucose (C) and plasma insulin levels (D). The Spearman’s
correlation coefficient was calculated and the significance level
was set at p,0.05.
(TIF)
Figure 4. In vivo SCFA uptake fluxes correlate inversely with metabolic syndrome markers. Correlation of acetate, propionate and
butyrate host uptake fluxes with body weight (A), AW/BW (B), hepatic triglycerides (C) and HOMA-IR (D). The Spearman’s correlation coefficient was
calculated and the significance level was set at p,0.05.
doi:10.1371/journal.pone.0107392.g004
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Figure S3 Correlation of bacterial production fluxes of acetate,
propionate and butyrate with cecal SCFA concentrations (A), body
weight (B), adipose body weight ratio (C), plasma triglycerides (D),
hepatic triglycerides (E), plasma glucose (F) and plasma insulin
levels (G) and HOMA-IR (H). The Spearman’s correlation
coefficient was calculated and the significance level was set at
p,0.05.
(TIF)
Table S1 Correlation of cecal acetate, propionate and butyrate
concentration with genes involved in SCFA transport, gluconeo-
genesis, glycolysis, fatty acid synthesis and fatty acid oxidation.
The Spearman’s correlation coefficient was calculated and the
significance level was set at p,0.05.
(DOCX)
Table S2 Correlation of acetate, propionate and butyrate host
uptake fluxes with genes involved in SCFA transport, gluconeo-
genesis, glycolysis, fatty acid synthesis and fatty acid oxidation.
The Spearman’s correlation coefficient was calculated and the
significance level was set at p,0.05.
(DOCX)
Table S3 Correlation of bacterial production fluxes of acetate,
propionate and butyrate with genes involved in SCFA transport,
gluconeogenesis, glycolysis, fatty acid synthesis and fatty acid
oxidation. The Spearman’s correlation coefficient was calculated
and the significance level was set at p,0.05.
(DOCX)
Text S1 Model description.
(DOC)
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